Advertisement
Screener

Alkermes plc. (ALKS) Graph

ALKS Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $496.01M; Cost of revenue $98.11M; Research and development $112.92M; Selling, general and administrative $217.63M.
  • 2026-03-31: Revenue $392.91M; Cost of revenue $61.58M; Research and development $103.34M; Selling, general and administrative $264.59M.
  • 2025-12-31: Revenue $384.55M*; Cost of revenue $46.21M*; Research and development $93.04M*; Selling, general and administrative $187.20M*.
  • 2025-09-30: Revenue $394.19M; Cost of revenue $51.59M; Research and development $81.74M; Selling, general and administrative $171.77M.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

ALKS revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Product$411.72MRoyalty$63.38MAristada AndAristada Initio$96.72MLUMRYZ$96.57MLYBALVI$93.98MManufacturedProduct And Royalty$84.28MManufacturing Revenue$20.90MVivitrol$124.45MRevenue$496.01MCost of revenue$98.11MOperating income$18.35MOther income, net$352.00KResearch & development$112.92MSelling, general& administrative$217.62MPre-tax income-$1.88MNet income$501.00K

Business Acquisition

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

ALKS revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.AvadelPharmaceuticals Plc$96.60MRevenue$496.01MCost of revenue$98.11MOperating income$18.35MOther income, net$352.00KResearch & development$112.92MSelling, general& administrative$217.62MPre-tax income-$1.88MNet income$501.00K

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2026-06-30$496.01M$98.11M$112.92M$217.63M-$2.38M$501.00K
2026-03-31$392.91M$61.58M$103.34M$264.59M$4.55M-$66.48M
2025-12-31$384.55M*$46.21M*$93.04M*$187.20M*$11.04M*$49.38M*
2025-09-30$394.19M$51.59M$81.74M$171.77M$17.98M$82.76M
2025-06-30$390.66M$49.46M$77.37M$170.85M$17.74M$87.10M
2025-03-31$306.51M$49.20M$71.82M$171.70M$3.02M$22.46M
2024-09-30$378.14M$63.10M$59.89M$150.38M$17.43M$92.38M
2024-06-30$399.13M$61.47M$59.65M$168.11M$22.06M$91.36M
2024-03-31$350.37M$58.64M$67.61M$179.75M$7.96M$36.83M
2023-09-30$380.94M$61.50M$64.88M$156.37M$1.15M$47.76M
2023-06-30$617.40M$63.25M$68.22M$195.76M$2.73M$237.06M
2023-03-31$287.60M$58.16M$63.77M$167.83M$717.00K-$41.84M
2022-09-30$252.36M$50.63M$100.43M$152.78M-$3.39M-$63.97M
2022-06-30$276.22M$58.36M$92.87M$150.38M-$3.11M-$30.14M
2022-03-31$278.55M$55.16M$95.95M$145.05M-$9.10M-$35.90M
2021-09-30$294.14M$49.56M$118.41M$136.21M$2.45M-$28.99M
2021-06-30$303.72M$53.12M$97.47M$139.19M$3.29M$2.36M
2021-03-31$251.43M$41.02M$92.27M$125.17M$3.77M-$22.42M
2020-09-30$265.01M$43.13M$94.98M$127.65M$2.33M-$134.00K
2020-06-30$247.53M$45.05M$94.22M$132.03M$3.67M-$29.43M
2020-03-31$246.22M$47.21M$93.28M$133.37M$7.33M-$38.65M
2019-09-30$255.24M$42.32M$107.67M$148.70M-$983.00K-$52.88M
2019-06-30$279.87M$46.22M$104.44M$155.07M$1.60M-$41.99M
2019-03-31$223.10M$45.36M$102.57M$141.22M-$3.85M-$96.40M
2018-09-30$248.72M$39.41M$101.27M$128.78M$611.00K-$34.44M
2018-06-30$304.64M$43.42M$106.82M$138.26M$8.20M-$32.65M
2018-03-31$225.15M$44.48M$108.35M$118.15M-$4.49M-$62.51M
2017-09-30$217.38M$36.05M$104.41M$99.63M$486.00K(m)
2017-06-30$218.84M$39.77M$99.15M$108.95M-$2.68M(m)
2017-03-31$191.78M(m)$104.83M$102.10M-$3.71M(m)
2016-09-30$180.24M(m)$99.44M$91.14M-$2.65M(m)
2016-06-30$195.16M(m)$97.01M$96.12M-$520.00K(m)
2016-03-31$156.77M(m)$101.07M$89.72M$404.00K(m)
2015-09-30$152.65M(m)$92.56M$89.50M$3.00M(m)
2015-06-30$151.37M(m)$87.88M$71.54M$3.06M(m)
2015-03-31$161.21M(m)$70.28M$63.05M$510.00K(m)
2014-09-30$159.99M(m)$78.26M$51.89M$3.52M(m)
2014-06-30$153.42M(m)$67.21M$50.66M-$1.52M(m)
2014-03-31$130.21M(m)$52.14M$42.55M$3.77M(m)
2013-09-30$139.80M(m)$45.95M$39.45M$233.00K(m)
2013-06-30$138.63M(m)$33.46M$32.93M$2.72M(m)
2013-03-31$163.42M(m)$35.80M$34.68M$4.87M(m)
2012-12-31$135.91M(m)$31.32M$29.87M$4.41M(m)
2012-09-30$123.98M(m)$35.09M$31.43M$422.00K(m)
2012-06-30$152.24M(m)$37.81M$29.78M$764.00K(m)
2011-12-31$125.64M(m)$40.49M$35.47M$98.00K-$14.83M
2011-09-30$71.98M(m)$28.16M$36.23M$3.65M-$22.25M
2011-06-30$61.88M(m)$28.05M$31.50M-$54.00K(m)
2010-12-31$43.98M(m)$22.50M$20.52M$41.00K-$11.38M
2010-09-30$49.25M(m)$23.93M$18.44M-$943.00K-$7.67M

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2026-06-30$888.92M$159.69M$216.26M$482.22M$2.18M-$65.98M
2025-06-30$697.17M$98.66M$149.19M$342.55M$20.77M$109.56M
2024-06-30$749.50M$120.12M$127.26M$347.86M$30.02M$128.19M
2023-06-30$904.99M$121.41M$132.00M$363.59M$3.44M$195.22M
2022-06-30$554.76M$113.52M$188.83M$295.43M-$12.21M-$66.04M
2021-06-30$555.15M$94.14M$189.74M$264.36M$7.06M-$20.05M
2020-06-30$493.75M$92.26M$187.50M$265.40M$11.00M-$68.08M
2019-06-30$502.97M$91.58M$207.00M$296.30M-$2.25M-$138.39M
2018-06-30$529.79M$87.89M$215.17M$256.40M$3.71M-$95.15M
2017-06-30$410.62M$80.19M$203.99M$211.05M-$6.39M(m)
2016-06-30$351.94M(m)$198.08M$185.84M-$116.00K(m)
2015-06-30$312.58M(m)$158.16M$134.59M$3.57M(m)
2014-06-30$283.64M(m)$119.35M$93.21M$2.24M(m)
2013-09-30$278.43M(m)$79.41M$72.39M$2.95M(m)
2013-06-30$302.05M(m)$69.26M$67.61M$7.58M(m)
2012-09-30$276.22M(m)$72.89M$61.21M$1.19M(m)
2011-09-30$133.86M(m)$56.21M$67.73M$3.60M-$35.49M
2010-09-30$91.53M(m)$46.91M$38.16M-$1.00M-$21.07M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2025-09-30$1.09B$150.25M$230.93M$514.33M$38.75M$192.32M
2024-09-30$1.13B$183.22M$187.15M$498.24M$47.46M$220.57M
2023-09-30$1.29B$182.91M$196.87M$519.96M$4.60M$242.98M
2022-09-30$807.12M$164.14M$289.26M$448.21M-$15.60M-$130.01M
2021-09-30$849.29M$143.71M$308.15M$400.57M$9.51M-$49.04M
2020-09-30$758.76M$135.39M$282.48M$393.05M$13.33M-$68.22M
2019-09-30$758.22M$133.90M$314.68M$445.00M-$3.23M-$191.27M
2018-09-30$778.51M$127.30M$316.43M$385.18M$4.32M-$129.60M
2017-09-30$628.00M$116.24M$308.40M$310.68M-$5.90M(m)
2016-09-30$532.18M(m)$297.52M$276.99M-$2.77M(m)
2015-09-30$465.24M(m)$250.72M$224.09M$6.57M(m)
2014-09-30$443.63M(m)$197.61M$145.10M$5.77M(m)
2013-12-31$432.91M(m)$128.13M$116.56M-$12.25M$17.65M
2013-09-30$441.86M(m)$115.21M$107.07M$7.82M(m)
2012-12-31$412.13M(m)$104.21M$91.08M$5.59M(m)
2011-12-31$259.50M(m)$96.70M$103.20M$3.69M-$50.32M
2010-12-31$135.50M(m)$69.41M$58.68M-$960.00K-$32.46M

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2025-12-31$1.48B$196.46M$323.96M$701.52M$49.79M$241.70M
2024-12-31$1.56B$245.33M$245.33M$645.24M$71.61M$367.10M
2023-12-31$1.66B$253.04M$270.81M$689.75M-$97.64M$355.80M
2022-12-31$1.11B$218.07M$272.70M$590.75M$2.02M-$158.30M
2021-12-31$1.17B$197.32M$290.92M$549.61M$11.33M-$48.20M
2020-12-31$1.04B$178.32M$394.59M$538.83M$14.32M-$110.86M
2019-12-31$1.17B$180.38M$512.83M$599.45M-$436.00K-$196.62M
2018-12-31$1.09B$176.42M$425.41M$526.41M$12.34M-$139.31M
2017-12-31$903.37M$154.75M$412.89M$421.58M$14.67M-$157.94M
2016-12-31$745.69M$132.12M$387.15M$374.13M-$5.94M-$208.44M
2015-12-31$628.34M(m)$344.40M$311.56M$3.16M-$227.16M
2014-12-31$618.79M(m)$272.04M$199.91M$16.03M-$30.06M
2013-12-31$596.33M(m)(m)(m)-$7.38M(m)
2013-03-31$575.55M(m)$140.01M$125.76M$10.46M$24.98M
2012-03-31$389.98M(m)$141.89M$137.63M-$714.00K-$113.68M
2011-03-31$186.64M(m)$97.24M$82.85M-$951.00K-$45.54M
2010-03-31$178.28M(m)$95.36M$76.51M-$5.08M-$39.63M

Similar stocks

Stock NameCountryMarket CapPE Ratio
RHYTHM PHARMACEUTICALS, INC. (RYTM)United States$6.771B-37.20
IONIS PHARMACEUTICALS INC (IONS)United States$7.277B-23.25
Liquidia Corp (LQDA)United States$6.347B51.23
Amneal Pharmaceuticals, Inc. (AMRX)$6.326B25.62
Spyre Therapeutics, Inc. (SYRE)United States$7.685B-43.69
Structure Therapeutics Inc. (GPCR)United States$7.710B-53.41
Praxis Precision Medicines, Inc. (PRAX)United States$7.884B-27.60
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Travere Therapeutics, Inc. (TVTX)United States$5.712B-123.10
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76